BCTX

BCTX

USD

BriaCell Therapeutics Corp. Common Shares

$10.960-0.120 (-1.083%)

Echtzeitkurs

Healthcare
Biotechnologie
Kanada

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$11.080

Hoch

$11.542

Tief

$10.800

Volumen

0.07M

Unternehmensfundamentaldaten

Marktkapitalisierung

20.6M

Branche

Biotechnologie

Land

Canada

Handelsstatistiken

Durchschnittliches Volumen

0.08M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $3.5Aktuell $10.960Hoch $98.2

Ähnliche Nachrichten

GlobeNewswire

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate

Mehr anzeigen
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
GlobeNewswire

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation

Mehr anzeigen
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer

Mehr anzeigen
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
GlobeNewswire

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA

Mehr anzeigen
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer